Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Treasury Secretary Geithner Talks Health Care Reforms In Beijing Visit

This article was originally published in The Pink Sheet Daily

Executive Summary

As Chinese are freed from saving for potentially massive health care costs, their strengthened spending power will fuel China’s economic expansion, Geither predicts.

You may also be interested in...

Barack Obama's Meeting With Chinese President Bodes Well For Pan-Pacific Pharma Partnerships, Says Analyst During Shanghai Conference

SHANGHAI - Despite the financial maelstrom that has lashed economies from the Americas to Asia, U.S. President Barack Obama's April 1 meeting with Chinese President Hu Jintao is ultimately likely to boost the pharmaceutical sector in each country and the potential for pan-Pacific partnerships, according to the chief executive officer of the San Diego-based consulting firm BioForesight

China Set To Launch Sweeping Health System Reforms, Aimed In Part At Reversing Stratified Access To Medicine, Hospitals, Insurance

BEIJING - China's central government is set to launch sweeping reforms of the country's health system, with the ultimate goal of providing universal health care by the year 2020

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts